国际动态存档 （2015年8月5期）

• 8/31 Alnylam, Medicines Co. Cholesterol Shot Exceeds Expectations, Lasts 140 Days
• 8/31 UPDATED: It's confirmed: 'No signal' of heart failure risk with Merck's Januvia
• 8/31 FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain
• 8/31 5 Big FDA Decisions Expected in September
• 8/31 Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 
• 8/31 Researchers Use DNA ‘Clews’ to Shuttle CRISPR-Cas9 Gene-Editing Tool into Cells
• 8/31 Cancer Immunotherapy Meets Precision Medicine in Biomarker Study
• 8/31 Precision medicine, linked to DNA, still too often misses, In cancer treatment, precision medicine is less precise than promised
• 8/31 UC San Diego cancer researchers receive NCI Outstanding Investigator Award 
• 8/31 Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval
• 8/28 China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up
• 8/28 Telesta Receives FDA BLA Filing Notification Letter and Priority Review Designation for MCNA(1) 
• 8/28 FDA warns of severe, disabling joint-pain risk with DPP-4 inhibitors 
• 8/28 GSK/Lilly pulmonary hypertension combo continues to impress 
• 8/28 Eli Lilly and partner pitch new diabetes drug Synjardy Approved: Metformin + Jardiance 
• 8/28 Long-Awaited Biosimilar Naming Rules : What to Call Biologic Copycats? FDA Plans Names And Suffixes 
• 8/28 The DNA damage response goes viral: A way in for new cancer treatments
• 8/28 Cancer drugs aren’t just really expensive; they’re a bad value
• 8/28 Lilly, Boehringer amp up fight against Lantus with U.K. biosim launch
• 8/28 FDA approves Repatha to treat certain patients with high cholesterol
• 8/27 Analyst Notes: The race is on between AstraZeneca and Clovis to capitalise on the EGFR-TKI resistant NSCLC population
• 8/27 Nanoparticles Hit Cancer’s Moving Target
• 8/27 Chimeric Antigen Receptor Pioneer Sees Solid Tumor Potential
• 8/27 Genmab/Janssen’s daratumumab benefits patients with drug-resistant multiple myeloma in Phase I/II trial 
• 8/27 Lilly and Boehringer launch Lantus biosimilar in UK
• 8/27 After two deaths, Verastem defends safety of experimental cancer drug
• 8/27 Pfizer posts positive Trumenba vaccine data
• 8/27 Brand Development Strategies: Golden Oldies
• 8/27 MSK: 'This is what the future of precision medicine looks like'
• 8/27 Lilly wins again in Alimta patent row with Teva 
• 8/27 Glaxo in $1 Billion Ofatumumab Deal With Novartis 
• 8/26 Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market
• 8/26 3 Reasons Why Afrezza's Launch Has Been So Disappointing
• 8/26 Generic Drug Sponsors Will Get Status Reports-- But Only For Old ANDAs
• 8/26 Bristol-Myers, Sanofi catch a break in Plavix marketing case
• 8/26 Exelixis' Cancer Drug Cometriq Gets Breakthrough Therapy Status for Renal Cell Carcinoma 
• 8/26 Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application
• 8/26 China-based biotech BeiGene to build manufacturing plant in Suzhou
• 8/26 Allele Biotech Takes Major Step into Nano Antibody Leadership Position
• 8/26 Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies
• 8/25 China Resilient: New Pharma Survey Offers Highly Positive Outlook
• 8/25 Stock slide makes biopharma deals more enticing for Gilead (and everyone else)
• 8/25 Mylan Launches Generic Zosyn Injection